Coursera Flash Sale
40% Off Coursera Plus for 3 Months!
Grab it
This video presentation from the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute provides a concise 21-minute summary of key kidney cancer clinical updates from GU ASCO 2025. Explore important findings including the COSMIC313 Triplet therapy study which demonstrated improved progression-free survival (PFS) but no overall survival (OS) benefit in first-line clear cell renal cell carcinoma (ccRCC), the KEYMAKER-U03 investigation of novel immune and targeted therapy approaches for refractory ccRCC, and promising research on KIM1 as a potential prognostic and predictive biomarker for immunotherapy benefit in ccRCC patients.
